Idiopathic triglyceride deposit cardiomyovasculopathy
Conditions
Interventions
Digoxin 0.25 mg and Rosuvastatin Calcium 5 mg or CNT-01 1000 mg, Digoxin 0.25 mg and Rosuvastatin Calcium 5 mg are administered orally.
Sponsors
Akita Yasuhiko
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Subjects who have signed the written informed consent. 2) Subjects 18 to 40 years of age at time of informed consent. 3) Subjects with body weight >=50 kg and body mass index (BMI) of 18.5 to 25.0 kg/m2 (inclusive) at the Screening Visit.
Exclusion criteria
Exclusion criteria: 1) Subjects with complications or past history of medically significant gastrointestinal, renal, respiratory, endocrine, hematological, nervous system, psychiatric, cardiovascular, or congenital metabolic disorders. 2) Subjects with acute illness within 2 weeks prior to administration of the drugs used in the Clinical Trial. 3) Subjects with a current or past history of drug or food allergy. 4) Subjects whose serum potassium or magnesium levels are below the institutional normal ranges at the Screening Visit. 5) Subjects whose serum calcium level is above the institutional normal range at the Screening Visit. 6) Subjects whose serum thyroid stimulating hormone, free triiodothyronine, or thyroxine levels are above the institutional normal ranges at the Screening Visit. 7) Subjects with a history of infection requiring treatment within 4 weeks prior to administration of the drugs used in the Clinical Trial. 8) Subjects with a positive SARS-CoV-2 test (nucleic acid amplification test) performed within 3 days before admission to the clinical site or suspected COVID-19 infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics | — |
Contacts
Public ContactClinical Development Dept.
TOA EIYO LTD.
Outcome results
None listed